Bronx New York Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center

• Category: Corporations - Public - Licenses
• State: Multi-State
• County: Bronx
• Control #: US-EG-9161
• Format: Word; Rich Text

Description

Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages A Bronx, New York Collateral License Agreement is a comprehensive document outlining the terms and conditions of the agreement between Gentling, Inc. and The University of North Texas Health Science Center. This agreement allows Gentling, Inc. to utilize and license certain intellectual property or inventions developed by The University of North Texas Health Science Center in the field of biomedical research or pharmaceutical development. It is crucial to clearly specify the scope and limitations of the agreement to protect the rights and interests of both parties involved. The Bronx, New York Collateral License Agreement typically includes several key components: 1. Parties Involved: The agreement begins by clearly identifying the parties involved, namely Gentling, Inc. and The University of North Texas Health Science Center. 2. Grants and Licenses: This section outlines the specific rights and licenses granted by The University of North Texas Health Science Center to Gentling, Inc. These can include exclusive or non-exclusive rights to use, manufacture, market, and sell intellectual property or inventions. 3. Intellectual Property: This part details the specific intellectual property or inventions covered by the agreement. It may include patents, copyrights, trademarks, or any other form of intellectual property developed by The University of North Texas Health Science Center. The agreement should clearly define the ownership and scope of the intellectual property involved. 4. Financial Considerations: The Bronx, New York Collateral License Agreement typically addresses financial arrangements such as upfront fees, milestone payments, royalties, and any other applicable financial obligations and terms. This section ensures that both parties clearly understand their financial responsibilities. 5. Term and Termination: The agreement specifies the duration of the license granted and the conditions for termination. It may also include provisions for renewal or extension of the agreement if mutually agreed upon by both parties. 6. Confidentiality and Non-Disclosure: This section ensures the protection of confidential information shared between the parties during the course of the agreement. It establishes guidelines and restrictions on the use and disclosure of proprietary information. 7. Dispute Resolution: The Bronx, New York Collateral License Agreement typically includes a clause for dispute resolution, outlining the preferred method for resolving conflicts, such as negotiation, mediation, or arbitration. It's important to note that different variations or types of Bronx, New York Collateral License Agreements may exist between Gentling, Inc. and The University of North Texas Health Science Center. These variations could involve specific industry sectors, therapeutic areas, or unique terms relevant to their collaboration. However, the core components mentioned above generally remain consistent across these agreements.

A Bronx, New York Collateral License Agreement is a comprehensive document outlining the terms and conditions of the agreement between Gentling, Inc. and The University of North Texas Health Science Center. This agreement allows Gentling, Inc. to utilize and license certain intellectual property or inventions developed by The University of North Texas Health Science Center in the field of biomedical research or pharmaceutical development. It is crucial to clearly specify the scope and limitations of the agreement to protect the rights and interests of both parties involved. The Bronx, New York Collateral License Agreement typically includes several key components: 1. Parties Involved: The agreement begins by clearly identifying the parties involved, namely Gentling, Inc. and The University of North Texas Health Science Center. 2. Grants and Licenses: This section outlines the specific rights and licenses granted by The University of North Texas Health Science Center to Gentling, Inc. These can include exclusive or non-exclusive rights to use, manufacture, market, and sell intellectual property or inventions. 3. Intellectual Property: This part details the specific intellectual property or inventions covered by the agreement. It may include patents, copyrights, trademarks, or any other form of intellectual property developed by The University of North Texas Health Science Center. The agreement should clearly define the ownership and scope of the intellectual property involved. 4. Financial Considerations: The Bronx, New York Collateral License Agreement typically addresses financial arrangements such as upfront fees, milestone payments, royalties, and any other applicable financial obligations and terms. This section ensures that both parties clearly understand their financial responsibilities. 5. Term and Termination: The agreement specifies the duration of the license granted and the conditions for termination. It may also include provisions for renewal or extension of the agreement if mutually agreed upon by both parties. 6. Confidentiality and Non-Disclosure: This section ensures the protection of confidential information shared between the parties during the course of the agreement. It establishes guidelines and restrictions on the use and disclosure of proprietary information. 7. Dispute Resolution: The Bronx, New York Collateral License Agreement typically includes a clause for dispute resolution, outlining the preferred method for resolving conflicts, such as negotiation, mediation, or arbitration. It's important to note that different variations or types of Bronx, New York Collateral License Agreements may exist between Gentling, Inc. and The University of North Texas Health Science Center. These variations could involve specific industry sectors, therapeutic areas, or unique terms relevant to their collaboration. However, the core components mentioned above generally remain consistent across these agreements.